Remove Compounding Remove Labelling Remove Packaging
article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 This is projected to grow at the highest compound annual growth rate of 5.27

Packaging 118
article thumbnail

Electronic smart packaging market to value nearly $3b in 2033

European Pharmaceutical Review

A market report has identified that global demand for electronic smart packaging will reach $2.6 This represents a compound annual growth rate (CAGR) of 15.4 A largely addressable market means that there is continued interest in smart packaging worldwide. billion in 2033. percent from 2023, according to the data.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Extemporaneous Compounding

RX Note

Introduction In 2018, the Ministry of Health Malaysia published the Good Compounding Practice as a guidance for compounding practices. NOTE: When compounding a preparation using the contents of an ampoule , care should be taken to withdraw the solution using a filter needle to avoid incorporating glass particles into the compound.

article thumbnail

What is cross contamination in pharmaceutical industry

GMPSOP

Cross contamination in the pharmaceutical industry can be described as an accidental inclusion of product of another batch or unknown foreign material into a finished batch, which was not intended or not mentioned on the label. Store all labels and leaflets in a locked room. Cross contamination data that can make you nervous!

article thumbnail

FDA guidance highlights E&L considerations for ophthalmic drug products

European Pharmaceutical Review

Therefore, extractables and leachables assessment should consider the packaging components of the CCS, including the labelling. However, according to the FDA, this is “less of a concern” for products, such as biological products, that are packaged in glass containers.

article thumbnail

Extemporaneous Preparation with Unknown Stability

RX Note

Today, stability information can be obtained from manufacturer’s labelling information (such as in the package insert), the USP compounding monographs, or peer-reviewed articles and references , such as articles in American Journal of Health-System Pharmacy, the International Journal of Pharmaceutical Compounding.

article thumbnail

5 Instances Of Challenging Antibiotic Workflows

ID Stewardship

Read all about this in the product label here. More information on ganciclovir in the label here. Compounding sulbactam-durlobactam Admittedly I have never compounded this one myself, but it just sounds like an error waiting to happen as well as a considerable time commitment. Well, maybe not. Have another one?